Table 1: List of prepandemic H5 LAIVs prepared on A/Leningrad/134/17/57 (H2N2) MDV backbone.

LAIV Candidate,
Genome Composition		 Wild–type Parental Virus Generated by Stage Study Refs.
Len–dP (H5N2),
7:11 		A/duck/Potsdam/1402–6/86 (H5N2) Classical reassortment Phase I–II clinical trials completed. The vaccine is registered in Russia [32, 33, 39]
Len–tT2 (H5N2),
7:11 		A/turkey/Turkey/1/2005 (H5N1), clade 2.2 Classical reassortment Phase I clinical trial completed [17]
Len–Vn2 (H5N2),
7:11 		A/Vietnam/1203/2004 (H5N1), clade 1 Classical reassortment Preclinical studies completed [17]
Len–Vn/rg2 (H5N1),
6:23 		A/Vietnam/1203/2004 (H5N1), clade 1 Reverse genetics Preclinical studies completed [30, 32]
Len–Eg/rg2 (H5N1),
6:23 		A/Egypt/321/2007
(H5N1), clade 2.2		 Reverse genetics Studies in mice [31]

1Vaccine strain inherited only HA gene from wild–type parental virus and remaining 7 genes – from Len–MDV (7:1 genome composition). 2ΔHA, polybasic cleavage site deleted. 3Vaccine strain inherited HA and NA genes from wild–type parental virus and remaining 6 genes – from Len–MDV (6:2 genome composition).